Three months ago Avient finally gave investors what they had been waiting for: a guidance raise across EBITDA, earnings per share and free cash flow, backed by sales volumes that turned positive sooner than management had feared. That broke a run of calls in which the company mostly held its outlook steady and talked about contingency planning. The third-quarter report, due before the open on November 4, will show whether that turn was the start of a durable recovery or a quarter that flattered the trend.

The Street expects earnings of $0.80 a share on revenue of about $855.9 million. That would be roughly 14% earnings growth and 6% revenue growth from a year ago, which is solid but not spectacular. The Earnings Whisper of $0.82 sits slightly above consensus, a modest nudge rather than a sign of a much higher bar. The sequential drop from last quarter's $0.96 reflects normal seasonality and should not alarm anyone. More telling is how the Street views the full year. Management lifted its 2026 EPS outlook to $3.10 to $3.25 from $2.93 to $3.17, yet consensus sits at $3.08, just below the bottom of the new range. Analysts are not fully buying the raise, most likely because management deliberately left the fourth quarter wide, citing limited visibility and the chance that pricing benefits fade.

That pricing question is central. About three-quarters of last quarter's 4.3% organic growth came from price and only a quarter from volume. A business cannot grow on price indefinitely, so this report needs to show volume carrying more of the load. Management said seven of nine end markets grew in the second quarter and expected eight of nine to grow in the third. Hitting that breadth target would strongly support the recovery story. Falling short, especially if price does most of the work again, would revive doubts about the quality of growth.

Several specific threads deserve attention. Packaging grew at a double-digit rate after a flat 2025. Building and construction also grew double digits on data center and infrastructure work, and Asia jumped 18%. Investors should want evidence that these were not one-quarter spikes. Healthcare, a former double-digit grower, was hurt by customer inventory rebalancing, and management expects a second-half recovery. Early signs of that rebound would ease one of the clearest drags. Transportation is expected to stay soft, so continued weakness there should not surprise anyone. Margins are another test after a record 18.3% adjusted EBITDA margin. Holding most of that expansion would show the gains came from mix and productivity rather than temporary price capture. Finally, the third quarter is the first full period since the EU's August deadline on PFAS in food packaging, which makes it a useful early read on Avient's non-PFAS processing aids, even if the revenue is still small.

The market has rewarded the raise without getting carried away. Shares are up about 3% since the last report while the S&P 500 slipped slightly, and the stock trades above its 200-day moving average. At $41.28, though, it sits well below its post-earnings high of $46.64, so some of the initial enthusiasm has faded. Sentiment is still bearish but less so than before the last report, suggesting skepticism is easing rather than turning into conviction.

The main question is whether Avient can show that volume, not just pricing, is driving its growth. Broad end-market growth, steady margins and enough confidence to narrow the fourth-quarter range would argue that the raised outlook is conservative and would pull the Street toward it. A price-heavy quarter with a still-cloudy year-end would suggest analysts were right to stay near the bottom of the range.